Have a personal or library account? Click to login
Prognostic value of plasma EBV DNA for nasopharyngeal cancer patients during treatment with intensity-modulated radiation therapy and concurrent chemotherapy Cover

Prognostic value of plasma EBV DNA for nasopharyngeal cancer patients during treatment with intensity-modulated radiation therapy and concurrent chemotherapy

Open Access
|Apr 2018

References

  1. Zhang W, Chen Y, Chen L, Guo R, Zhou G, Tang L, et al. The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases. <em>Medicine</em> (<em>Baltimore</em>) 2015; <bold>94</bold>: e845. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1097/md.0000000000000845" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1097/md.0000000000000845</a></pub-id>
  2. Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, et al. Analysis of plasma Epstein-Barr Virus DNA to screen for nasopharyngeal cancer. <em>N Engl J Med</em> 2017; <bold>377</bold>: 513-22. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1056/NEJMoa1701717" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1056/NEJMoa1701717</a></pub-id>
  3. Peng H, Guo R, Chen L, Zhang Y, Li WF, Mao YP, et al. Prognostic impact of plasma Epstein-Barr Virus DNA in patients with nasopharyngeal carcinoma treated using intensity-modulated radiation therapy. <em>Sci Rep</em> 2016; <bold>6</bold>: 22000. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1038/srep22000" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/srep22000</a></pub-id>
  4. Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. <em>J Natl Cancer Inst</em> 2002; <bold>94</bold>: 1614-9.
  5. Leung SF, Zee B, Ma BB, Hui EP, Mo F, Lai M, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. <em>J Clin Oncol</em> 2006; <bold>24</bold>: 5414-8. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1200/jco.2006.07.7982" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/jco.2006.07.7982</a></pub-id>
  6. Tang LQ, Li CF, Chen QY, Zhang L, Lai XP, He Y, et al. High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort study. <em>Int J Radiat Oncol Biol Phys</em> 2015; <bold>91</bold>: 325-36. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.ijrobp.2014.10.005" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ijrobp.2014.10.005</a></pub-id>
  7. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. <em>N Engl J Med</em> 2004; <bold>350</bold>: 2461-70. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1056/NEJMoa032260" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1056/NEJMoa032260</a></pub-id>
  8. Twu CW, Wang WY, Liang WM, Jan JS, Jiang RS, Chao J, et al. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. <em>Int J Radiat Oncol Biol Phys</em> 2007; <bold>67</bold>: 130-7. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.ijrobp.2006.07.012" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ijrobp.2006.07.012</a></pub-id>
  9. Alfieri S, lacovelli NA, Marceglia S, Lasorsa I, Resteghini C, Taverna F, et al. Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area. <em>Oncotarget</em> 2017; <bold>8</bold>: 47780-9. <pub-id pub-id-type="doi"><a href="https://doi.org/10.18632/oncotarget.17822" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.18632/oncotarget.17822</a></pub-id>
  10. Wei W, Huang Z, Li S, Chen H, Zhang G, Li S, et al. Pretreatment Epstein-Barr virus DNA load and cumulative cisplatin dose intensity affect long-term outcome of nasopharyngeal carcinoma treated with concurrent chemotherapy: experience of an institute in an endemic area. <em>Oncol Res Treat</em> 2014; <bold>37</bold>: 88-95. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1159/000360178" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1159/000360178</a></pub-id>
  11. Wang WY, Twu CW, Chen HH, Jan JS, Jiang RS, Chao JY, et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. <em>Clin Cancer Res</em> 2010; <bold>16</bold>: 1016-24. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1158/1078-0432.ccr-09-2796" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/1078-0432.ccr-09-2796</a></pub-id>
  12. Prayongrat A, Chakkabat C, Kannarunimit D, Hansasuta P, Lertbutsayanukul C. Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma. <em>J Radiat Res</em> 2017; <bold>58</bold>: 509-16. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1093/jrr/rrw128" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/jrr/rrw128</a></pub-id>
  13. Hou X, Zhao C, Guo Y, Han F, Lu LX, Wu SX, et al. Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. <em>Clin Oncol</em> (<em>R Coll Radiol</em>) 2011; <bold>23</bold>: 128-33. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.clon.2010.09.001" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.clon.2010.09.001</a></pub-id>
  14. Lee VH, Kwong DL, Leung TW, Choi CW, Lai V, Ng L, et al. Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma. <em>Oncotarget</em> 2017; <bold>8</bold>: 5292-308. <pub-id pub-id-type="doi"><a href="https://doi.org/10.18632/oncotarget.14137" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.18632/oncotarget.14137</a></pub-id>
  15. Twu CW, Wang WY, Chen CC, Liang KL, Jiang RS, Wu CT, et al. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. <em>Int J Radiat Oncol Biol Phys</em> 2014; <bold>89</bold>: 21-9. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.ijrobp.2014.01.052" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ijrobp.2014.01.052</a></pub-id>
  16. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. <em>J Clin Oncol</em> 1998; <bold>16</bold>: 1310-7. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1200/jco.1998.16.4.1310" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/jco.1998.16.4.1310</a></pub-id>
  17. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage Ill and IV nasopharyngeal cancer of the endemic variety. <em>J Clin Oncol</em> 2005; <bold>23</bold>: 6730-8. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1200/jco.2005.16.790" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1200/jco.2005.16.790</a></pub-id>
  18. Lee AW, Tung SY, Chua DT, Ngan RK, Chappell R, Tung R, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs. radiotherapy alone for regionally advanced nasopharyngeal carcinoma. <em>J Natl Cancer Inst</em> 2010; <bold>102</bold>: 1188-98. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1093/jnci/djq258" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/jnci/djq258</a></pub-id>
  19. Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, et al. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial. <em>Eur J Cancer</em> 2017; <bold>75</bold>: 150-8. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.ejca.2017.01.002" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ejca.2017.01.002</a></pub-id>
  20. Lo YM, Leung SF, Chan LY, Chan AT, Lo KW, Johnson PJ, et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. <em>Cancer Res</em> 2000; <bold>60</bold>: 2351-5.
  21. Leung SF, Chan KC, Ma BB, Hui EP, Mo F, Chow KC, et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. <em>Ann Oncol</em> 2014; <bold>25</bold>: 1204-8. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1093/annonc/mdu117" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/annonc/mdu117</a></pub-id>
  22. Songthong AP, Kannarunimit D, Chakkabat C, Lertbutsayanukul C. A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events. <em>Radiat Oncol</em> 2015; <bold>10</bold>: 166. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1186/s13014-015-0472-y" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1186/s13014-015-0472-y</a></pub-id>
  23. Liu TB, Zheng ZH, Pan J, Pan LL, Chen LH. Prognostic role of plasma Epstein-Barr virus DNA load for nasopharyngeal carcinoma: a meta-analysis. <em>Clin Invest Med</em> 2017; <bold>40</bold>: E1-e12.
  24. Lertbutsayanukul C, Prayongrat A, Kannarunimit D, Chakkabat C, Netsawang B, Kitpanit S. A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma. <em>Strahlenther Onkol</em> 2018. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1007/s00066-017-1251-5" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s00066-017-1251-5</a></pub-id>. [Epub ahead of print]
  25. Su SF, Han F, Zhao C, Chen CY, Xiao WW, Li JX, et al. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone. <em>Int J Radiat Oncol Biol Phys</em> 2012; <bold>82</bold>: 327-33. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.ijrobp.2010.09.011" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ijrobp.2010.09.011</a></pub-id>
  26. Xiao WW, Han F, Lu TX, Chen CY, Huang Y, Zhao C. Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma. <em>Int J Radiat Oncol Biol Phys</em> 2009; <bold>74</bold>: 1070-6. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.ijrobp.2008.09.008" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ijrobp.2008.09.008</a></pub-id>
DOI: https://doi.org/10.2478/raon-2018-0016 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 195 - 203
Submitted on: Dec 21, 2017
Accepted on: Feb 4, 2018
Published on: Apr 28, 2018
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year

© 2018 Chawalit Lertbutsayanukul, Danita Kannarunimit, Anussara Prayongrat, Chakkapong Chakkabat, Sarin Kitpanit, Pokrath Hansasuta, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.